Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danvatirsen and Durvalumab in Advanced Pancreatic, NSCLC, and CRC
NCT02983578Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2017
- Primary completion
- Aug 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of danvatirsen in pancreatic cancer (PC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Disease Control Rate at 4 months, Tumor-based biomarkers up to 4 years and 1 more. Started Mar 2017; status: active, not recruiting.
02
Drugs
danvatirsen
03
Conditions
pancreatic cancer (PC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02983578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983578.